154 related articles for article (PubMed ID: 12356992)
1. Epistaxis after sildenafil.
Bott SR; Shergill I; Arya M
J R Soc Med; 2002 Oct; 95(10):528. PubMed ID: 12356992
[No Abstract] [Full Text] [Related]
2. [Therapy of erectile dysfunction. Hard facts support sildenafil].
MMW Fortschr Med; 2003 Sep; 145(35-36):50-1. PubMed ID: 14584211
[No Abstract] [Full Text] [Related]
3. Acute priapism associated with the use of sildenafil in a patient with sickle cell trait.
Kassim AA; Fabry ME; Nagel RL
Blood; 2000 Mar; 95(5):1878-9. PubMed ID: 10744389
[No Abstract] [Full Text] [Related]
4. Tachyphylaxis and phosphodiesterase type 5 inhibitors.
Steers WD
J Urol; 2002 Jul; 168(1):207. PubMed ID: 12050542
[No Abstract] [Full Text] [Related]
5. Epistaxis after PDE-5 inhibitors misuse.
Pomara G; Morelli G; Menchini-Fabris F; Dinelli N; Campo G; LiGuori G; Selli C
Int J Impot Res; 2006; 18(2):213-4. PubMed ID: 16107867
[TBL] [Abstract][Full Text] [Related]
6. New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
Mason RG
J R Soc Promot Health; 2003 Jun; 123(2):79-80. PubMed ID: 12852189
[No Abstract] [Full Text] [Related]
7. Re: Long-term efficacy of sildenafil and tachyphylaxis effect.
Carson CC
J Urol; 2002 Jul; 168(1):205. PubMed ID: 12073960
[No Abstract] [Full Text] [Related]
8. Sildenafil increases cerebrovascular reactivity: a transcranial Doppler study.
Brenner S
Neurology; 2006 May; 66(9):1455-6; author reply 1455-6. PubMed ID: 16682690
[No Abstract] [Full Text] [Related]
9. Inhibition of type-5 phosphodiesterase: promising therapy for pulmonary hypertension.
Watanabe H
Intern Med; 2004 Oct; 43(10):891-3. PubMed ID: 15575233
[No Abstract] [Full Text] [Related]
10. [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].
Chen Q; Wang N; Yao F; Lu X
Zhonghua Nan Ke Xue; 2004 Apr; 10(4):302-4. PubMed ID: 15148932
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
Kloner RA
Circulation; 2004 Nov; 110(19):3149-55. PubMed ID: 15533876
[No Abstract] [Full Text] [Related]
12. Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized.
Manganiello V
Mol Pharmacol; 2003 Jun; 63(6):1209-11. PubMed ID: 12761329
[No Abstract] [Full Text] [Related]
13. Sildenafil: emerging cardiovascular indications.
Raja SG; Nayak SH
Ann Thorac Surg; 2004 Oct; 78(4):1496-506. PubMed ID: 15464535
[TBL] [Abstract][Full Text] [Related]
14. Fatal variceal rupture after sildenafil use: report of a case.
Finley DS; Lugo B; Ridgway J; Teng W; Imagawa DK
Curr Surg; 2005; 62(1):55-6. PubMed ID: 15708146
[TBL] [Abstract][Full Text] [Related]
15. Sildenafil can increase the response to inhaled nitric oxide.
Bigatello LM; Hess D; Dennehy KC; Medoff BD; Hurford WE
Anesthesiology; 2000 Jun; 92(6):1827-9. PubMed ID: 10839936
[No Abstract] [Full Text] [Related]
16. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
Reffelmann T; Kloner RA
Circulation; 2003 Jul; 108(2):239-44. PubMed ID: 12860892
[No Abstract] [Full Text] [Related]
17. The discovery of novel, potent and selective PDE5 inhibitors.
Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
Bioorg Med Chem Lett; 2001 Sep; 11(18):2461-4. PubMed ID: 11549447
[TBL] [Abstract][Full Text] [Related]
18. Intracerebral hemorrhage associated with sildenafil use: a case report.
Alpsan MH; Bebek N; Ciftci FD; Coban O; Bahar S; Tuncay R
J Neurol; 2008 Jun; 255(6):932-3. PubMed ID: 18465112
[No Abstract] [Full Text] [Related]
19. Oral drug treatment of erectile dysfunction.
Int J Impot Res; 2003 Dec; 15 Suppl 7():S27-9. PubMed ID: 14695970
[No Abstract] [Full Text] [Related]
20. Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil.
Gibson A
Eur J Pharmacol; 2001 Jan; 411(1-2):1-10. PubMed ID: 11137852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
